Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study
Open Access
- 3 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Glioblastoma (GBM) is the most common and aggressive type of tumour arising from the central nervous system. GBM remains an incurable disease despite advancement in therapies, with overall survival of approximately 15 months. Recent literature has highlighted that GBM releases tumoural content which crosses the blood-brain barrier (BBB) and is detected in patients’ blood, such as circulating tumour cells (CTCs). CTCs carry tumour information and have shown promise as prognostic and predictive biomarkers in different cancer types. Currently, there is limited data for the clinical utility of CTCs in GBM. Here, we report the use of spiral microfluidic technology to isolate CTCs from whole blood of newly diagnosed GBM patients before and after surgery, followed by characterization for GFAP, cell-surface vimentin protein expression and EGFR amplification. CTCs were found in 13 out of 20 patients (9/20 before surgery and 11/19 after surgery). Patients with CTC counts equal to 0 after surgery had a significant longer recurrence-free survival(p=0.0370). This is the first investigation using the spiral microfluidics technology for the enrichment of CTCs from GBM patients and these results support the use of this technology to better understand the clinical value of CTCs in the management of GBM in future studies.Keywords
Funding Information
- Cancer Australia
- National Health and Medical Research Council
- Garnett Passe and Rodney Williams Memorial Foundation
- Cure Brain Cancer Foundation
This publication has 47 references indexed in Scilit:
- Circulating biomarkers in patients with glioblastomaBritish Journal of Cancer, 2019
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yetOncotarget, 2017
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- Liquid biopsy for brain tumorsExpert Review of Molecular Diagnostics, 2017
- Second surgery for recurrent glioblastoma: A concise overview of the current literatureClinical Neurology and Neurosurgery, 2016
- Challenges in circulating tumour cell researchNature Reviews Cancer, 2014
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Standards of care for treatment of recurrent glioblastoma—are we there yet?Neuro-Oncology, 2012
- A fluid biopsy as investigating technology for the fluid phase of solid tumorsPhysical Biology, 2012
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005